In this issue:
21-gene assay to predict chemotherapy benefit in node +ve breast cancer
Ipilimumab and nivolumab in unresectable/metastatic metaplastic breast cancer
p70S6K/AKT inhibition + paclitaxel in HER2 –ve advanced breast cancer
Probiotic supplement attenuates CRCI in breast cancer
Brain white matter microstructure: risk factor for CRCI
Adjuvant tamoxifen adherence in men with early-stage breast cancer
Fulvestrant vs. letrozole, with palbociclib, for hormone receptor +ve advanced breast cancer
Personalised vs. physician's choice therapy for residual triple –ve breast cancer
Adjuvant palbociclib for early breast cancer
Effect of elective IMNI on DFS in node +ve breast cancer
Please login below to download this issue (PDF)